<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Gene Therapy | BM Sci-Tech Memento</title>
    <link>https://example.com/tag/gene-therapy/</link>
      <atom:link href="https://example.com/tag/gene-therapy/index.xml" rel="self" type="application/rss+xml" />
    <description>Gene Therapy</description>
    <generator>Wowchemy (https://wowchemy.com)</generator><language>en-us</language><lastBuildDate>Mon, 28 Nov 2022 00:00:00 +0000</lastBuildDate>
    <image>
      <url>https://example.com/media/icon_hu1efa9af2edf414d45fb59503b457ea16_13437_512x512_fill_lanczos_center_3.png</url>
      <title>Gene Therapy</title>
      <link>https://example.com/tag/gene-therapy/</link>
    </image>
    
    <item>
      <title>Species-agnostic polymeric formulations for inhalable messenger RNA delivery to the lung</title>
      <link>https://example.com/article/36443576/</link>
      <pubDate>Mon, 28 Nov 2022 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/36443576/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Messenger RNA has now been used to vaccinate millions of people. However, the diversity of pulmonary pathologies, including infections, genetic disorders, asthma and others, reveals the lung as an important organ to directly target for future RNA therapeutics and preventatives. Here we report the screening of 166 polymeric nanoparticle formulations for functional delivery to the lungs, obtained from a combinatorial synthesis approach combined with a low-dead-volume nose-only inhalation system for mice. We identify P76, a poly-Î²-amino-thio-ester polymer, that exhibits increased expression over formulations lacking the thiol component, delivery to different animal species with varying RNA cargos and low toxicity. P76 allows for dose sparing when delivering an mRNA-expressed Cas13a-mediated treatment in a SARS-CoV-2 challenge model, resulting in similar efficacy to a 20-fold higher dose of a neutralizing antibody. Overall, the combinatorial synthesis approach allowed for the discovery of promising polymeric formulations for future RNA pharmaceutical development for the lungs.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Exosome-mediated delivery of Cas9 ribonucleoprotein complexes for tissue-specific gene therapy of liver diseases</title>
      <link>https://example.com/article/36103526/</link>
      <pubDate>Wed, 14 Sep 2022 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/36103526/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;CRISPR-Cas9 gene editing has emerged as a powerful therapeutic technology, but the lack of safe and efficient in vivo delivery systems, especially for tissue-specific vectors, limits its broad clinical applications. Delivery of Cas9 ribonucleoprotein (RNP) owns competitive advantages over other options; however, the large size of RNPs exceeds the loading capacity of currently available delivery vectors. Here, we report a previously unidentified genome editing delivery system, named exosome&lt;sup&gt;RNP&lt;/sup&gt;, in which Cas9 RNPs were loaded into purified exosomes isolated from hepatic stellate cells through electroporation. Exosome&lt;sup&gt;RNP&lt;/sup&gt; facilitated effective cytosolic delivery of RNP in vitro while specifically accumulated in the liver tissue in vivo. Exosome&lt;sup&gt;RNP&lt;/sup&gt; showed vigorous therapeutic potential in acute liver injury, chronic liver fibrosis, and hepatocellular carcinoma mouse models via targeting p53 up-regulated modulator of apoptosis (&lt;em&gt;PUMA&lt;/em&gt;), cyclin E1 (&lt;em&gt;CcnE1&lt;/em&gt;), and K (lysine) acetyltransferase 5 (&lt;em&gt;KAT5&lt;/em&gt;), respectively. The developed exosomeRNP provides a feasible platform for precise and tissue-specific gene therapies of liver diseases.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Journey to the Center of the Cell: Tracing the Path of AAV Transduction</title>
      <link>https://example.com/review/33071047/</link>
      <pubDate>Thu, 15 Oct 2020 00:00:00 +0000</pubDate>
      <guid>https://example.com/review/33071047/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;As adeno-associated virus (AAV)-based gene therapies are being increasingly approved for use in humans, it is important that we understand vector-host interactions in detail. With the advances in genome-wide genetic screening tools, a clear picture of AAV-host interactions is beginning to emerge. Understanding these interactions can provide insights into the viral life cycle. Accordingly, novel strategies to circumvent the current limitations of AAV-based vectors may be explored. Here, we summarize our current understanding of the various stages in the journey of the vector from the cell surface to the nucleus and contextualize the roles of recently identified host factors.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/review/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Reviews &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Engineering adeno-associated virus vectors for gene therapy</title>
      <link>https://example.com/review/32042148/</link>
      <pubDate>Mon, 10 Feb 2020 00:00:00 +0000</pubDate>
      <guid>https://example.com/review/32042148/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Adeno-associated virus (AAV) vector-mediated gene delivery was recently approved for the treatment of inherited blindness and spinal muscular atrophy, and long-term therapeutic effects have been achieved for other rare diseases, including haemophilia and Duchenne muscular dystrophy. However, current research indicates that the genetic modification of AAV vectors may further facilitate the success of AAV gene therapy. Vector engineering can increase AAV transduction efficiency (by optimizing the transgene cassette), vector tropism (using capsid engineering) and the ability of the capsid and transgene to avoid the host immune response (by genetically modifying these components), as well as optimize the large-scale production of AAV.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/review/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Reviews &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Adeno-associated virus vector as a platform for gene therapy delivery</title>
      <link>https://example.com/review/30710128/</link>
      <pubDate>Fri, 01 Feb 2019 00:00:00 +0000</pubDate>
      <guid>https://example.com/review/30710128/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Adeno-associated virus (AAV) vectors are the leading platform for gene delivery for the treatment of a variety of human diseases. Recent advances in developing clinically desirable AAV capsids, optimizing genome designs and harnessing revolutionary biotechnologies have contributed substantially to the growth of the gene therapy field. Preclinical and clinical successes in AAV-mediated gene replacement, gene silencing and gene editing have helped AAV gain popularity as the ideal therapeutic vector, with two AAV-based therapeutics gaining regulatory approval in Europe or the United States. Continued study of AAV biology and increased understanding of the associated therapeutic challenges and limitations will build the foundation for future clinical success.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/review/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Reviews &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
  </channel>
</rss>
